PierianDx Management Team
18 Team Members
PierianDx has 18 executives. PierianDx's founder is Jeffrey D. Millbrandt. PierianDx's current Founder, President is Rakesh Nagarajan.
You May Also Like
Navican provides a personalized approach to testing, diagnosing, and treating cancer. The company's unique process analyzes the genetic makeup of a patient's cancer and employs a team of skilled molecular tumor specialists to review each test and determine how to most effectively treat that cancer case.
Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.
Fabric Genomics, formerly Omicia, is a computational genomics company offering end-to-end genomic data analysis, annotation, curation, classification and reporting solutions to clinical labs, hospital labs, country sequencing programs and life science companies. Fabric Genomics' analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for high throughout panels, exomes, and whole genomes. The company can process any NGS file input (e.g. FASTQ, BAM or VCF) providing alignment, variant calling, annotation, guideline-driven variant classification, variant interpretation and clinical reporting for both hereditary disease and oncology. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics, and is headquartered in Oakland, California with satellite offices in London, Seattle, Salt Lake City and Boston. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.
Gene42 is a medical technology and clinical software company that develops clinical software tools for collecting and analyzing phenotypic information for patients with genetic disorders and cancers. Their solution, PhenoTips, allows for efficient recording of patient data in a standardized format, which facilitates automated searches of annotated genes and disease databases (differential diagnosis), enables effortless querying and sharing of anonymized patient data by users and provides a user-friendly interface with advanced features that reduces clinician's workload and seamlessly integrates into clinical work flow. Gene42 provides support contracts and custom development for PhenoTips software. Data organization when it comes to patient care is critical, especially in rare diseases when certain symptoms or features of a disease might not be seen on a regular basis. In the age of "big data" and electronic health records, Gene42 is striving to make personalized medicine more effective for patients and their doctors.
Q-State Biosciences is a precision medicine company creating new genetically targeted medicines for people living with nervous system disorders. The company's proprietary ResQueTM Platform incorporates a suite of technologies to map each patient’s unique genome to a genetic therapy that targets the root cause of disease.
Illumina works to apply new technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. The company was founded in 1998 and is based in San Diego, California.